Tissue Repair Ltd · ASX:TRP
Tissue Repair — Shareholder Meeting (November 2025)
19 slides from Tissue Repair's shareholder meeting presentation, Nov 24, 2025
Slide 1: AGM Company Update
For personal use only AGM Company Update Tony Charara CEO and Co-Founder
Slide 2: Agenda
Agenda For personal use only Brief tech recap TR Pro+® product line - product strategy and commercialisation TR-987 drug update Conclusion and Questions 2
Slide 3: Beta Glucans are an overlooked molecule with significant promise
Beta Glucans are an overlooked molecule with significant promise, known for their powerful immunomodulating pathways for over 40 years. . .we are the only company globally with a drug in development for wound healing For personal use only with the most optimal molecule from this family • Key challen
Slide 4: Patented proprietary optimised glucan molecule for wound healing
We have patented a proprietary optimised glucan molecule by composition, structure, source and purity which we believe is the most powerful to date designed for wound healing. . . importantly with a standardised immune response for a given dose For personal use only • There are literally thousands o
Slide 5: Glucoprime doubles the number of M2 macrophages
Glucoprime doubles the number of M2 Macrophages, our MOA acts on the prized “M1:M2” transition use only • There were no significant differences seen in M1 macrophage numbers at day 3 or day 7 in the two treatment groups. • There was a significant increase of 45% in M2 macrophages seen at day 7 in th
Slide 6: The company is pursuing two strong opportunities
The company is pursuing two strong opportunities competing for capital and resources . . . Mission For personal use only ● Significant amount of work over 4 years on manufacturing Core analytics and tox/safety and several FDA meeting requests and Achieve a Chronic Wounds guidance to achieve phase II
Slide 7: Agenda
Agenda For personal use only Brief Tech Recap TR Pro+® product line - product strategy and commercialisation TR-987 drug update Conclusion and Questions 7
Slide 8: TR product line up - a new category of regenerative wound healing
TR product line up - a new category of regenerative wound healing TR Pro+® Gel TR Renew TR S For personal use only TR Med Gel TR Ferrin Gel Serum 5 year mission ● Global revenue opportunity AUD50-AUD100m pa ● Broad based access to a new class of regenerative medicine products for dermatology, aesthe
Slide 9: Extract of Dr Leiw's presentation on the launch of TR Pro
Extract of Dr Leiw’s presentation on the launch of TR Pro “a new disruptor of wound healing . . moves us from passive healing to active healing of wounds” For personal use only Supercharged macrophages Wound burn +9 days after treatment Same wound 10 days post treatment with existing wound bandages
Slide 10: Tissue Repair acute wound product strategy
Tissue Repair acute wound product strategy . . . AESTHETICS CHANNEL MEDICAL CHANNEL For personal use only PRODUCTS TR Pro+ TR Renew Serum TR Med TR S TR Ferrin Glucoprime Glucoprime Glucoprime & Anti Glucoprime Carbomer Niacinamide Glucoprime FORMULATION microbial agent Silicone gel Ethanol Hyaluron
Slide 11: Tissue Repair Portfolio – Recommended Usage
Tissue Repair Portfolio – Recommended Usage Days to epithelialisation Days 0 3 5 7 10 14 TR Pro+® Gel For personal use only TR Pro+® TR Renew Non-ablative laser Serum Ablative laser Microneedling TR Renew Chemical peel Serum Injection Reconstructive and cosmetic surgery Days to epithelialisation Med
Slide 12: TR Pro+ commercial experience with only one SKU
Tr Pro+® commercial experience with only one SKU, “a 10 Gram Tube” For personal use only • “A boot strapped” TR sales team - achieved distribution to c200-300 clinics • Significant revenue growth over 12 months to 30 June 25 at c178%pa (compounded monthly growth rate of 9.68% pm) to achieve c$78k pe
Slide 13: Agenda
Agenda For personal use only Brief Tech Recap TR Pro+® product line - product strategy and commercialisationcialisation TR-987 drug update Conclusion and Questions 13
Slide 14: Phase III Trial strategy has evolved
Phase III Trial strategy has evolved . . . Managing our risk of the phase III trial program June 2027 For personal use only Nov 2025 June 2026 Total c35 patients Target c100 patients Last patient randomised to date randomised randomised 10 in screening Green light interim analysis for futility only
Slide 15: Phase II data showed a 60% delta over placebo
Our phase II trial data showed a 60% delta over placebo in percent wound area reduction [p<0.03] . . we are powering this signal in our phase III trial with an improved design giving us conviction over a successful outcome For personal use only
Slide 16: A note on IP
A note on IP . . . Our tech is backed by a strong patent portfolio granted in the US and currently being expanded to other global territories For personal use only US Divisional Patent METHOD OF MAKING A BETAGLUCAN COMPOUND Glucoprime GRANTED ® Methods of manufacture •The claims allowed cover the me
Slide 17: Regulatory Exclusivity is also available as a New Chemical Entity
Regulatory Exclusivity is also available as a New Chemical Entity For personal use only Regulatory ® Glucoprime meets the FDA criteria of A New Chemical Entity (NCE). There is no drug substance exclusivity currently approved globally for any indication based on Tissue Repair’s engineered molecule. T
Slide 18: Agenda
Agenda For personal use only Brief Tech Recap TR Pro+® product line - product strategy and commercialisation TR-987 drug update TR-987 drug update TR-987 drug and Conclusion updatercialisation Questions TR-987 drug update 18
Slide 19: Important notice and disclaimer
Important notice and disclaimer This presentation (Presentation) is dated 18/09/2023 and has been prepared by Tissue Repair Ltd (ACN 158 411 566) (Tissue Repair or the Company). Information in this Presentation The information in this Presentation is of a general background nature for informational